STAT3-IN-18 

STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.

STAT3-IN-18 (0.5 μM; 48 h) inhibits the phosphorylation of STAT3 and JAK2, decreases the protein levels of Bcl-2 and COX-2, and increases the protein levels of Bak, Caspase-3, Cleaved PARP1 in MDA-MB-231 cells^[1].
STAT3-IN-18 (0.5μM; 36 h) arrests the cell cycle of MDA-MB-231 cells at S phase, (0.5 μM; 48 h) and induces apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

STAT3-IN-18 (refers to 1.5 mg Pt; every 2 days for 18 days) results inhibition of STAT3 phosphorylation, and inhibits tumor growth in 4T1 xenograft tumor mice model. The median lethal dose (LD50) of DPP is 10.45 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

630.38

C₁₈H₂₄Cl₂N₂O₆Pt

2668267-41-0

[Cl-][Pt+4]([Cl-])([NH3])([NH3])([OH-])[O-]C(COC(C=C1)=CC=C1/C=C/C2=CC(OC)=CC(OC)=C2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cai L, Wang Y, Chen H, Tan Y, Yang T, Zhang S, Guo Z, Wang X. Platinum(IV) Complexes as Inhibitors of STAT3 and Regulators of the Tumor Microenvironment To Control Breast Cancer. J Med Chem. 2023 Aug 24;66(16):11351-11364.  [Content Brief]